Qinotto

Executive Summary

Qinotto is a private, early-stage biopharmaceutical company focused on overcoming the blood-brain barrier (BBB) to deliver large molecule therapeutics to the central nervous system (CNS). Founded in 2021 and based in San Francisco, the company has developed a proprietary BBB transport platform called QinoTrans, which has identified novel targets enabling CNS delivery of biologics that are otherwise restricted. This technology addresses a critical unmet need, as less than 1% of large molecules can cross the BBB, limiting treatment options for neurological diseases such as Alzheimer's, Parkinson's, and brain tumors. While Qinotto is still in the preclinical stage with no disclosed pipeline candidates or funding details, its platform approach differentiates it from traditional CNS drug developers. The company's success hinges on validating QinoTrans in vivo and securing partnerships or financing to advance lead programs. If successful, Qinotto could unlock a large addressable market and enable a new class of CNS therapeutics. However, given the early stage, execution risk remains high. The conviction score reflects the promising platform but limited data and visibility.

Upcoming Catalysts (preview)

• Q4 2026Preclinical in vivo proof-of-concept data for lead candidate40% success
• Q4 2026IND-enabling studies initiation or completion30% success
• Q3 2026Strategic partnership or licensing deal with a larger pharma25% success